Clinical Trials

Clinical Trials

Our Current Trials

A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa

This Phase 3 trial is recruiting. Learn more at ClinicalTrials.gov – Identifier NCT04213261

For more information about the DeFi-Phase 3 Study, visit DeFi-RDEB.com

A Phase 1/2 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

This Phase 1/2 trial is active, but not recruiting. Learn more at ClinicalTrials.gov – Identifier NCT02810951

A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

This Phase 1/2 trial is currently recruiting adult patients. Learn more at ClinicalTrials.gov – Identifier NCT03740724